Odylia Therapeutics: RPGRIP1 Gene Therapy to Treat RPGRIP1 related vision loss (September, 2021)

Odylia Therapeutics' CSO, Ashley Winslow, and Director of Development, Heather Greene, discuss Odylia's RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6), Cone rod dystrophy 13 (CORD13), and juvenile Retinitis Pigmentosa caused by mutations in RPGRIP1.To support the RPGRIP1 program follow the link to donate: odyliatherapeutics.salsalabs....